预防心律失常装置感染试验:PADIT 试验
PADIT 为集群随机交叉试验,在 28 个中心、19,603 例心脏植入式电子装置手术患者中比较常规围术期抗生素与增量围术期抗生素方案。增量方案未显著降低装置感染住院率:总体感染 0.78% 对 1.03%(OR 0.77,95%CI 0.56–1.05,P=0.10),高危组 1.01% 对 1.23%(OR 0.82,95%CI 0.59–1.15,P=0.26)。
要点
- 增量围术期抗生素未显著降低装置感染住院率。
- 总体感染率低,常规方案组 1.03%,增量方案组 0.78%。
- 高危患者亚组分析未发现显著获益的人群或中心特征。
核心结论
- 增量围术期抗生素方案较常规头孢唑林未显著降低装置感染住院率。
研究设计与样本
- 集群随机交叉试验,4 个随机分配的 6 个月周期,中心内对所有心脏植入式电子装置手术统一采用常规或增量围术期抗生素。
- 共 28 个中心、19,603 例患者接受装置手术,其中高危患者 12,842 例。
主要发现
- 总体感染:常规治疗组 99 例(1.03%),增量治疗组 78 例(0.78%),OR 0.77,95%CI 0.56–1.05,P=0.10。
- 高危患者感染住院:常规抗生素组 77 例(1.23%),增量抗生素组 66 例(1.01%),OR 0.82,95%CI 0.59–1.15,P=0.26。
- 亚组分析未发现从增量治疗中显著获益的相关患者或中心特征。
关键数值与推荐
- 常规方案:术前头孢唑林静脉输注。
- 增量方案:术前头孢唑林加万古霉素、术中杆菌肽囊袋冲洗、术后口服头孢氨苄 2 天。
- 主要结局为高危组 1 年内因装置感染住院,采用分层 logistic 回归模型分析并校正随机集群与集群-周期效应。
临床怎么用
- 在装置感染率较低的中心,增量围术期抗生素未显示显著优于常规头孢唑林预防。
- 临床决策可结合本中心感染率与耐药菌流行病学,不宜仅依据本试验结果普遍加用增量抗生素。
局限性
- 原文摘要未报告增量方案的不良反应、耐药菌选择或成本等安全性/经济学结局。
- 主要结局差异未达统计学显著,亚组分析未识别显著获益人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Infection of implanted medical devices has catastrophic consequences. For cardiac rhythm devices, pre-procedural cefazolin is standard prophylaxis but does not protect against methicillin-resistant gram-positive organisms, which are common pathogens in device infections. OBJECTIVE: This study tested the clinical effectiveness of incremental perioperative antibiotics to reduce device infection. METHODS: The authors performed a cluster randomized crossover trial with 4 randomly assigned 6-month periods, during which centers used either conventional or incremental periprocedural antibiotics for all cardiac implantable electronic device procedures as standard procedure. Conventional treatment was pre-procedural cefazolin infusion. Incremental treatment was pre-procedural cefazolin plus vancomycin, intraprocedural bacitracin pocket wash, and 2-day post-procedural oral cephalexin. The primary outcome was 1-year hospitalization for device infection in the high-risk group, analyzed by hierarchical logistic regression modeling, adjusting for random cluster and cluster-period effects. RESULTS: Device procedures were performed in 28 centers in 19,603 patients, of whom 12,842 were high risk. Infection occurred in 99 patients (1.03%) receiving conventional treatment, and in 78 (0.78%) receiving incremental treatment (odds ratio: 0.77; 95% confidence interval: 0.56 to 1.05; p = 0.10). In high-risk patients, hospitalization for infection occurred in 77 patients (1.23%) receiving conventional antibiotics and in 66 (1.01%) receiving incremental antibiotics (odds ratio: 0.82; 95% confidence interval: 0.59 to 1.15; p = 0.26). Subgroup analysis did not identify relevant patient or site characteristics with significant benefit from incremental therapy. CONCLUSIONS: The cluster crossover design efficiently tested clinical effectiveness of incremental antibiotics to reduce device infection. Device infection rates were low. The observed difference in infection rates was not statistically significant. (Prevention of Arrhythmia Device Infection Trial [PADIT Pilot] [PADIT]; NCT01002911).
引用
- Krahn AD, Longtin Y, Philippon F, et al. Prevention of Arrhythmia Device Infection Trial: The PADIT Trial. J Am Coll Cardiol. 2018. PMID: 30545448. doi:10.1016/j.jacc.2018.09.068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。